Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,290,000.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the sale, the chief executive officer now directly owns 257,054 shares in the company, valued at $13,263,986.40. This trade represents a 8.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

David Alan Campbell also recently made the following trade(s):

• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $45.21 on Friday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -38.64 and a beta of 3.52. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $65.60. The firm’s 50-day simple moving average is $49.81 and its 200 day simple moving average is $45.80.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The business’s revenue was down 82.6% compared to the same quarter last year. On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on JANX. Wedbush reissued an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Scotiabank reduced their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, UBS Group assumed coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $67.70.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds have recently bought and sold shares of JANX. FMR LLC lifted its position in shares of Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after purchasing an additional 47,075 shares in the last quarter. Janus Henderson Group PLC increased its stake in Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after buying an additional 721,563 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares in the last quarter. Logos Global Management LP boosted its stake in shares of Janux Therapeutics by 400.0% in the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after buying an additional 600,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after acquiring an additional 38,490 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.